AR109895A1 - CYCLICAL COMPOUNDS OF TYPOSINE TYPEOSEPHYPE PEPTIDE AS NEUROPEPTIDE MODULATORS AND RECEPTORS - Google Patents
CYCLICAL COMPOUNDS OF TYPOSINE TYPEOSEPHYPE PEPTIDE AS NEUROPEPTIDE MODULATORS AND RECEPTORSInfo
- Publication number
- AR109895A1 AR109895A1 ARP170102979A ARP170102979A AR109895A1 AR 109895 A1 AR109895 A1 AR 109895A1 AR P170102979 A ARP170102979 A AR P170102979A AR P170102979 A ARP170102979 A AR P170102979A AR 109895 A1 AR109895 A1 AR 109895A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- ch2s
- conjugate
- absent
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000009435 amidation Effects 0.000 abstract 1
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 230000021235 carbamoylation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 230000029226 lipidation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019635 sulfation Effects 0.000 abstract 1
- 238000005670 sulfation reaction Methods 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), en donde p es 0 ó 1, m es 0, 1, 2, 3, 4 ó 5; n es1, 2, 3 ó 4; q es 0 ó 1; siempre que q sea 1 solo cuando Z³⁰ está ausente; PUENTE es -Ph-CH₂-S-, -triazolil-, -NHC(O)CH₂S-, -SCH₂C(O)NH-, -(OCH₂CH₂)₂NHC(O)CH₂S, -NHC(O)- o -CH₂S-; Z⁴ es K, A, E, S o R; Z⁷ es A o K; Z⁹ es G o K; Z¹¹ es D o K; Z²² es A o K; Z²³ es S o K; Z²⁶ es A o H; Z³⁰ es L, W, ausente, o K; siempre que Z³⁰ esté ausente solo cuando q es 1; Z³⁴ es un compuesto de fórmula (2) ó (3); Z³⁵ es un compuesto seleccionado del grupo de fórmulas (4); o un derivado de estos; en donde el derivado es el compuesto de la fórmula (1) que se modifica por uno o más procesos que comprenden amidación, glicosilación, carbamilación, sulfación, fosforilación, ciclización, lipidación o pegilación; o una sal farmacéuticamente aceptable de este. Reivindicación 7: Una composición farmacéutica que comprende un compuesto de una cualquiera de las reivindicaciones 1 a 5 o el conjugado de la reivindicación 6, y un portador farmacéuticamente aceptable. Reivindicación 9: Un método para prevenir, tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad se selecciona del grupo que consiste en: obesidad, diabetes tipo 2, síndrome metabólico, resistencia a la insulina y dislipidemia que comprende administrar a un sujeto que lo necesita una cantidad eficaz del compuesto de una cualquiera de las reivindicaciones 1 a 5, el conjugado de la reivindicación 6, o una forma, composición o medicamento de estos. Reivindicación 15: Un método para preparar una composición farmacéutica que comprende combinar el compuesto de una cualquiera de las reivindicaciones 1 a 5 o el conjugado de la reivindicación 6, con un portador farmacéuticamente aceptable.Claim 1: A compound of the formula (1), wherein p is 0 or 1, m is 0, 1, 2, 3, 4 or 5; n is 1, 2, 3 or 4; q is 0 or 1; provided that it is 1 only when Z³⁰ is absent; BRIDGE is -Ph-CH₂-S-, -triazolyl-, -NHC (O) CH₂S-, -SCH₂C (O) NH-, - (OCH₂CH₂) ₂NHC (O) CH₂S, -NHC (O) - or -CH₂S- ; Z⁴ is K, A, E, S or R; Z⁷ is A or K; Z⁹ is G or K; Z¹¹ is D or K; Z²² is A or K; Z²³ is S or K; Z²⁶ is A or H; Z³⁰ is L, W, absent, or K; provided that Z³⁰ is absent only when q is 1; Z³⁴ is a compound of formula (2) or (3); Z³⁵ is a compound selected from the group of formulas (4); or a derivative of these; wherein the derivative is the compound of the formula (1) that is modified by one or more processes comprising amidation, glycosylation, carbamylation, sulfation, phosphorylation, cyclization, lipidation or pegylation; or a pharmaceutically acceptable salt thereof. Claim 7: A pharmaceutical composition comprising a compound of any one of claims 1 to 5 or the conjugate of claim 6, and a pharmaceutically acceptable carrier. Claim 9: A method for preventing, treating or improving a syndrome, disorder or disease, wherein the syndrome, disorder or disease is selected from the group consisting of: obesity, type 2 diabetes, metabolic syndrome, insulin resistance and dyslipidemia that it comprises administering to an individual in need an effective amount of the compound of any one of claims 1 to 5, the conjugate of claim 6, or a form, composition or medicament thereof. Claim 15: A method of preparing a pharmaceutical composition comprising combining the compound of any one of claims 1 to 5 or the conjugate of claim 6, with a pharmaceutically acceptable carrier.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413586P | 2016-10-27 | 2016-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109895A1 true AR109895A1 (en) | 2019-01-30 |
Family
ID=65351710
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102981A AR110106A1 (en) | 2016-10-27 | 2017-10-26 | IMMUNOGLOBULINS AND USES OF THESE |
| ARP170102979A AR109895A1 (en) | 2016-10-27 | 2017-10-26 | CYCLICAL COMPOUNDS OF TYPOSINE TYPEOSEPHYPE PEPTIDE AS NEUROPEPTIDE MODULATORS AND RECEPTORS |
| ARP170102980A AR109979A1 (en) | 2016-10-27 | 2017-10-26 | CYCLICAL COMPOUNDS PEPTIDE TYPEOSINE-TYROSINE COUPLED TO ANTIBODIES AS MODULATORS OF NEUROPEPTIDE RECEPTORS AND |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102981A AR110106A1 (en) | 2016-10-27 | 2017-10-26 | IMMUNOGLOBULINS AND USES OF THESE |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102980A AR109979A1 (en) | 2016-10-27 | 2017-10-26 | CYCLICAL COMPOUNDS PEPTIDE TYPEOSINE-TYROSINE COUPLED TO ANTIBODIES AS MODULATORS OF NEUROPEPTIDE RECEPTORS AND |
Country Status (1)
| Country | Link |
|---|---|
| AR (3) | AR110106A1 (en) |
-
2017
- 2017-10-26 AR ARP170102981A patent/AR110106A1/en unknown
- 2017-10-26 AR ARP170102979A patent/AR109895A1/en unknown
- 2017-10-26 AR ARP170102980A patent/AR109979A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR109979A1 (en) | 2019-02-13 |
| AR110106A1 (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521431209B1 (en) | Glucagon-like Peptide 1 Receptor Agonists | |
| EA201590525A1 (en) | SLIP PROTEINS FOR THE TREATMENT OF METABOLIC SYNDROME | |
| EA201991316A1 (en) | CONJUGATES CONTAINING A GLP-1 / GLUCAGON DOUBLE AGONIST, LINKER AND HYALURONIC ACID | |
| UY38483A (en) | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS | |
| BR112013021236A2 (en) | compound, composition, and method of treating a disorder, condition or disease | |
| GT201500030A (en) | 1,4-DISPOSED PIRIDAZINE ANALOGS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO THE DEFICIENCY OF SMN | |
| EA201171197A8 (en) | SUBSTITUTED DERIVATIVES AZOANTHRACENE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION | |
| CL2012003211A1 (en) | Compounds derived from piperidinyl substituted lactams, modulators of gpr119; process to prepare the compounds; pharmaceutical composition comprising the compounds; and use of the compounds in the preparation of medicaments for the treatment or prevention of type 2 diabetes, obesity and related conditions | |
| PE20190912A1 (en) | PYRIDONE COMPOUND AS C-MET INHIBITOR | |
| EA201990388A1 (en) | CXCR7 PIPERIDINE MODULATORS | |
| EA201490489A1 (en) | PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7 | |
| MX380191B (en) | COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES. | |
| EA201491335A1 (en) | BIGUANID COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS | |
| BR112015003109A2 (en) | COMPOUND, COMPOSITION, USE OF A COMPOUND, AND, METHODS FOR TREAT OR PREVENT A DISORDER, CONDITION OR DISEASE AND FOR TREAT TYPE 2 DIABETES MELLITUS. | |
| CL2012001722A1 (en) | Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes. | |
| PE20171622A1 (en) | INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION | |
| CO2021002768A2 (en) | 2,6-diaminopyridine compounds | |
| AR108046A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE | |
| CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
| DK1856090T3 (en) | Substituted thiophene derivatives such as glucagon receptor antagonists, preparation and therapeutic applications | |
| PE20180412A1 (en) | INHIBITING COMPOUNDS OF THE NOTCH WAY SIGNALING | |
| EA201891267A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING EFFECTIVE URAT1 INHIBITOR | |
| EA201300436A1 (en) | JOINT CRYSTALS AND SALTS OF CCR3 INHIBITORS | |
| JP2016508506A5 (en) | ||
| EA201890534A1 (en) | NEW ANNELED PHENOXYCETAMIDES |